Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"We view Omidria sales as a means for OMER to fund one of the most exciting biotechnology pipelines in the industry." (4/8/15) Omeros Corp. - The Life Sciences Report Interview with Jason Kolbert More >
Ed Arce joined ROTH Capital Partners in December 2013 as a senior research analyst. Prior to ROTH, he covered biotechnology, biopharmaceutical, specialty pharmaceutical and select medical device companies as an analyst at MLV & Co. Prior to MLV, Arce covered the biotechnology sector at Wedbush Securities, and large-cap pharmaceuticals at UBS Securities. Arce started his equity research career in 2005 as a research associate at First Albany Capital, covering specialty and generic pharmaceutical companies. He holds a master of science degree in finance (MSF) degree from Boston College, as well as a master's degree in business administration and a bachelor's degree in civil engineering, both from Florida International University. Mr. Arce is a board-licensed professional engineer, and a Level III CFA candidate.
What Moves Biotech Stocks? Ed Arce Has Answers. (10/18/12) Biotech stocks move on material news, which means clinical data, regulatory progress, new partnerships and big contracts with new customers. Analyst Ed Arce of MLV & Co. holds to these principles as he shares compelling biotech names in this exclusive interview with The Life Sciences Report.
"INO has had a number of successes clinically and marquee collaborations that have led to its market cap being what it is today." (5/20/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Ross Silver More >
"Subsequent analysis of CANF's CF101 data shows promise in a certain subset of patients." (5/13/15) Can-Fite BioPharma Ltd. - The Life Sciences Report 2015 Small-Cap Biotech Watchlist Update with Reni Benjamin More >